PT  - JOURNAL ARTICLE
AU  - WALTER, THOMAS
AU  - REY, KATJA S.
AU  - WENDEL, HANS PETER
AU  - SZABO, SEBASTIAN
AU  - SUSELBECK, TIM
AU  - DEMPFLE, CARL-ERIK
AU  - BORGGREFE, MARTIN
AU  - SWOBODA, STEFANIE
AU  - BEYER, MARTIN E.
AU  - HOFFMEISTER, HANS MARTIN
TI  - Thrombogenicity of Sirolimus-eluting Stents and Bare Metal Stents: Evaluation in the Early Phase after Stent Implantation
DP  - 2010 Sep 01
TA  - In Vivo
PG  - 635--639
VI  - 24
IP  - 5
4099  - http://iv.iiarjournals.org/content/24/5/635.short
4100  - http://iv.iiarjournals.org/content/24/5/635.full
SO  - In Vivo2010 Sep 01; 24
AB  - Background: Thrombogenicitiy of drug-eluting stents is a matter of controversial debate. The aim of this study was to evaluate the thrombogenicity of sirolimus-eluting stents (SES) compared to bare metal stents (BMS) in a standardised in vitro model. Materials and Methods: Nine SES and nine BMS were implanted in tubing loops and nine loops without stent served as controls. Initially and after 90 minutes of blood circulation in a modified chandler loop model, thrombin-antithrombin III complex (TAT), PMN-elastase, factor XIIa, SC5b-9, sP-selectin and platelet count were measured. Expression of CD62P, CD45/41 and PAC-1 on platelets were determined by flow cytometry. Results: After 90 minutes, platelet count decreased significantly in the loops with BMS and SES (p<0.05). Levels of TAT, PMN-elastase and SC5b-9 were significantly elevated after 90 minutes in all loops (p<0.05). sP-selectin significantly increased in the loops with BMS and SES after 90 minutes. No significant changes occurred in any flow cytometric data. Platelet count, sP-selectin, TAT, PMN-elastase, SC5b-9, CD62P, CD41/CD45 and PAC-1 showed no significant difference between BMS and SES. Conclusion: These data provide evidence that there is no difference in thrombogenicity of BMS and SES in the in vitro model.